Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Abstract Background The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468). Methods Patients (≥ 18 years of age; N = 414) with active PsA were ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Peter Nash, Philip J. Mease, Iain B. McInnes, Proton Rahman, Christopher T. Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu, Luminita Pricop, on behalf of the FUTURE 3 study group
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2018-03-01
Colecção:Arthritis Research & Therapy
Assuntos:
Psoriatic arthritis
Secukinumab
Autoinjector
Interleukin-17a
FUTURE 3 study
Acesso em linha:http://link.springer.com/article/10.1186/s13075-018-1551-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados